Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...
RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...
GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback